4DMedical is trading at A$3.42, down -6.04%, with no clear company-specific announcement explaining the September 1, 2026 decline.

  • FY2026 results released August 28 showed A$7.06 million revenue, up 21%, and reduced adjusted losses, but identified no negative catalyst.
  • Broader market conditions were mixed rather than strongly risk-off, leaving attribution uncertain.
  • Further disclosure or delayed analyst commentary may clarify the move.